A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

J1O-MC-JZHC -

The reason for this study is to determine the recommended phase 2 dose of the study drug LY3295668 erbumine in participants with breast cancer that has spread to other parts of the body.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Breast Cancer
What the trial is testing?
Endocrine therapy, Erbumine, Midazolam
Could I receive a Placebo?
No
Enrollment Goal
5
Trial Dates
Aug 2, 2019 - May 14, 2020
How long will I be in the trial?
Your participation in this trial could last up to 23 months, depending on your cancer type and how you and your tumor respond.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.